Copenhagen-based Zealand Pharma has announced positive results from a Phase III confirmatory study investigating dasiglucagon in patients with severe hypoglycaemia related to diabetes.
Copenhagen-based Zealand Pharma has announced positive results from a Phase III confirmatory study investigating dasiglucagon in patients with severe hypoglycaemia related to diabetes.